Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 14, 2005 - Issue 7
Submit an article Journal homepage
191
Views
30
CrossRef citations to date
0
Altmetric
Review

CCR1 antagonists in clinical development

James E Pease Leukocyte Biology Section, Biomedical Sciences Division, Faculty of Medicine, Imperial College of Science, Technology & Medicine, South Kensington Campus, London SW7 2AZ, UK. [email protected]
&
Richard Horuk Berlex Biosciences, Department of Immunology, 2600 Hilltop Drive, Richmond, CA 94806, USA. [email protected]
Pages 785-796 | Published online: 15 Jul 2005

Bibliography

  • ZLOTNIK A, YOSHIE 0: Chemokines: a new classification system and their role in immunity. Immunity (2000) 12(2):121–127.
  • ROTA, VON ANDRIAN UH: Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Ann. Rev Immune]. (2004) 22:891–928.
  • GERARD C, ROLLINS BJ: Chemokines and disease. Nat. hmnunol. (2001) 2(2):108–115.
  • CASCIERI MA, SPRINGER MS: The chemokine/chemokine-receptor family: potential and progress for therapeutic intervention. Curl: Opin. Chem. Biol. (2000) 4(4):420–427.
  • ONUFFER JJ, HORUK R: Chemokines, chemokine receptors and small-molecule antagonists: recent developments. Trends Pharmacol Sci. (2002) 23(10):459–467.
  • NEOTE K, DIGREGORIO D, MAK JY, HORUK R, SCHALL TJ: Molecular cloning, functional expression, and signalling characteristics of a C-C chemokine receptor. Cell (1993) 72(3):415–425.
  • GAO J-L, KUHNS DB, TIFFANY HL et al: Structure and functional expression of the human macrophage inflammatory protein la/RANTES receptor. I Exp. Med. (1993) 177 (5): 1421–1427.
  • MONTECLARO FS, CHARO IF: The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/ MIP-la receptor, confers chemokine selectivity. Evidence for a two-step mechanism for MCP-1 receptor activation. J. Biol. Chem. (1996) 271(32):19084–19092.
  • PEASE JE, WANG J, PONATH PD, MURPHY PM: The N-terminal extracellular segments of the chemokine receptors CCR1 and CCR3 are determinants for MIP- la and eotaxin binding, respectively, but a second domain is essential for receptor activation. J. Biol. Chem. (1998) 273:19972–19976.
  • WONG M, FISH EN: RANTES and MIP-la activate stats in T cells. J. Biol. Chem. (1998) 273(1):309–314.
  • GONG X, GONG W, KUHNS DB et al:Monocyte chemotactic protein-2 (MCP-2) uses CCR1 and CCR2B as its functional receptors. J. Biol. Chem. (1997) 272:11682–11685.
  • YOUN BS, ZHANG SM, LEE EK et al:Molecular cloning of leukotactin-1: a novel human 13-chemokine, a chemoattractant for neutrophils, monocytes, and lymphocytes, and a potent agonist at CC chemokine receptors 1 and 3. J. Immunol (1997) 159:5201–5205.
  • SARAU HM, RUSH JA, FOLEY JJ et al: Characterization of functional chemokine receptors (CCR1 and CCR2) on EoL-3 cells: a model system to examine the role of chemokines in cell function. J. Pharmacol Exp. Ther. (1997) 283(1):411–418.
  • WEBER C, WEBER KS, KLIER C et al: Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and T (H)l-like/CD45R0(+) T cells. Blood (2001) 97(4):1144–1146.
  • EIS V, LUCKOW B, VIELHAUER V et al: Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction. I Am. Soc. Nephrol (2004) 15(2):337–347.
  • •This paper highlights a non-redundant role for CCR1 in inflammation.
  • BROXMEYER HE, COOPERS, HANGOC G, GAO JL, MURPHY PM: Dominant myelopoietic effector functions mediated by chemokine receptor CCR1. J. Exp. Med. (1999) 189(12):1987–1992.
  • •This paper highlights a non-redundant role for CCR1 in inflammation.
  • GAO JL, WYNN TA, CHANG Y et al: Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1. J. Exp. Med. (1997) 185(11):1959–1968.
  • •This paper highlights a non-redundant role for CCR1 in inflammation.
  • GERARD C, FROSSARD JL, BHATIA M et al.: Targeted disruption of the 13-chemokine receptor CCR1 protects against pancreatitis-associated lung injury. Clin. Invest. (1997) 100(8):2022–2027.
  • •This paper highlights a non-redundant role for CCR1 in inflammation.
  • KASAMA T, STRIETER RM, STANDIFORD TJ, BURDICK MD, KUNKEL SL: Expression and regulation of human neutrophil-derived macrophage inflammatory protein la. I Exp. Med. (1993) 178:63–72.
  • THORNTON S, DUWEL LE, BOIVIN GP, MAY, HIRSCH R: Association of the course of collagen-induced arthritis with distinct patterns of cytokine and chemokine messenger RNA expression. Arthritis Rheum. (1999) 42(6):1109–1118.
  • SZEKANECZ Z, HALLORAN MM, VOLIN MV et al: Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. Arthritis Rheum. (2000) 43(6):1266–1277.
  • KOCH AE, KUNKEL SL, HARLOW LA et al.: Macrophage inflammatory protein-la. A novel chemotactic cytokine for macrophages in rheumatoid arthritis. Clin. Invest. (1994) 93(3):921–928.
  • HATANO Y, KASAMA T, IWABUCHI H et al: Macrophage inflammatory protein 1a expression by synovial fluid neutrophils in rheumatoid arthritis. Ann. Rheum. Dis. (1999) 58(5):297–302.
  • SUZUKI N, NAKAJIMA A, YOSHINO S et al.: Selective accumulation of CCR5' T lymphocytes into inflamed joints of rheumatoid arthritis. Int. Immunol (1999) 11(4):553–559.
  • MACCHIONI P, BOIARDI L, MELICONI R et al.: Serum chemokines in patients with psoriatic arthritis treated with cyclosporin A. Rheumatol (1998) 25(2):320–325.
  • LISIGNOLI G, TONEGUZZI S, POZZI C et al: Chemokine expression by subchondral bone marrow stromal cells isolated from osteoarthritis (OA) and rheumatoid arthritis (RA) patients. Clin. Exp. Immunol (1999) 116(2):371–378.
  • BARNES DA, TSE J, KAUFHOLD M et al.: Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. Clin. Invest. (1998) 101(12):2910–2919.
  • BALASHOV KE, ROTTMAN JB, WEINER HL, HANCOCK WW: CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP- la and IP-10 are expressed in demyelinating brain lesions. Proc. Natl. Acad. Sci. USA (1999) 96(12):6873–6878.
  • McMANUS C, BERMAN JW, BRETT FM et al: MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. I. Neuroimmunol (1998) 86(1):20–29.
  • TREBST C, SORENSEN TL, KIVISAKK P et al.: CCR1*/CCR5* mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am. I Pathol (2001) 159(5):1701–1710.
  • TREBST C, STAUGAITIS SM, TUCKY B et al: Chemokine receptors on infiltrating leucocytes in inflammatory pathologies of the central nervous system (CNS). Neuropathol Appl. Neurobiol (2003) 29(6):584–595.
  • KIVISAKK P, TREBST C, LIU Z et al: T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking. Clin. Exp. Immunol (2002) 129(3):510–518.
  • RAJAN AJ, ASENSIO VC, CAMPBELL IL, BROSNAN CF: Experimental autoimmune encephalomyelitis on the SJL mouse: effect of y-8 T cell depletion on chemokine and chemokine receptor expression in the central nervous system. Immunol (2000) 164(4):2120–2130.
  • FISCHER FR, SANTAMBROGIO L, LUO Y et al.: Modulation of experimental autoimmune encephalomyelitis: effect of altered peptide ligand on chemokine and chemokine receptor expression. Neuroimmunol (2000) 110(1-2):195–208.
  • ROTTMAN JB, SLAVIN AJ, SILVA R et al.: Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. Eur Immunol (2000) 30(8):2372–2377.
  • ADAMS DH, HUBSCHER S, FEAR J et al.: Hepatic expression of macrophage inflammatory protein-la and macrophage inflammatory protein-13 after liver transplantation. Transplantation (1996) 61(5):817–825.
  • FAIRCHILD RL, VANBUSKIRK AM, KONDO T, WAKELY ME, OROSZ CG: Expression of chemokine genes during rejection and long-term acceptance of cardiac allografts. Transplantation (1997) 63(12):1807–1812.
  • FARVER CE RAYCHAUDHURI B, MALUR A et al.: Increased alveolar macrophage nuclear factor-KB activation and macrophage inhibitory protein-1a levels in lung transplant patients. Transplantation (2000) 70(11):1599–1603.
  • PATTISON J, NELSON PJ, HUIE P et al: RANTES chemokine expression in cell-mediated transplant rejection of the kidney. Lancet (1994) 343(8891):209–211.
  • PATTISON JM, NELSON PJ, HUIE P, SIBLEY RK, KRENSKY AM: RANTES chemokine expression in transplant-associated accelerated atherosclerosis. J. Heart Lung Transplant. (1996) 15(12):1194–1199.
  • AZZAWI M, HASLETON PS, GERAGHTY PJ et al.: RANTES chemokine expression is related to acute cardiac cellular rejection and infiltration by CD45R0 T-lymphocytes and macrophages. J. Heart Lung Transplant. (1998) 17(9):881–887.
  • BELPERIO JA, BURDICK MD, KEANE MP et al: The role of the CC chemokine, RANTES, in acute lung allograft rejection. J. Immunol (2000) 165(1):461–472.
  • GAO W, TOPHAM PS, KING JA et al: Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. Clin. Invest. (2000) 105(1):35–44.
  • •Proof-of-principle study showing that the targeting of CCR1 is of beneficial effect in the treatment of allograft rejection.
  • TERAN LM, NOSO N, CARROLL M et al.: Eosinophil recruitment following allergen challenge is associated with the release of the chemokine RANTES into asthmatic airways. Immunol (1996) 157:1806–1812.
  • POWELL N, HUMBERT M, DURHAM SR et al: Increased expression of mRNA encoding RANTES and MCP-3 in the bronchial mucosa in atopic asthma. Eur. Respir J. (1996) 9(12):2454–2460.
  • BERKMAN N, KRISHNAN VL, GILBEY T et al.: Expression of RANTES mRNA and protein in airways of patients with mild asthma. Am. I Respir. Grit. Care Med. (1997) 154:1804–1811.
  • HOLGATE ST, BODEY KS, JANEZIC A et al: Release of RANTES, MIP-la, and MCP-1 into asthmatic airways following endobronchial allergen challenge. Am. .1 Respir. Grit. Care Med. (1997)156(5):1377–1383.
  • RAJAKULASINGAM K, HAMID Q, O'BRIEN F et al: RANTES in human allergen-induced rhinitis: cellular source and relation to tissue eosinophilia. Am. Respir Grit. Care Med. (1997) 155:696–703.
  • ALAM R, YORK J, BOYARS M et al: Increased MCP-1, RANTES, and MIP-la in bronchoalveolar lavage fluid of allergic asthmatic patients. Am. I Respir. Grit. Care Med. (1996) 153(4 Part 0:1398–1404.
  • TILLIE-LEBLOND I, HAMMAD H, DESURMONT S et al: CC chemokines and interleukin-5 in bronchial lavage fluid from patients with status asthmaticus. Potential implication in eosinophil recruitment. Am. I Respir. Grit. Care Med. (2000) 162(2 Part 1):586–592.
  • KRAMER ME OSTERTAG P, PFROGNER E, RASP G: Nasal IL-16 and MIP-la in late-phase allergic response. Allergy Asthma Proc. (2001) 22(3):127–132.
  • BENSCH GW, NELSON HS, BORISH LC: Evaluation of cytokines in nasal secretions after nasal antigen challenge: lack of influence of antihistamines. Ann. Allergy Asthma Immunol (2002) 88(5):457–462.
  • KABURAGI Y, SHIMADA Y, NAGAOKA T et al: Enhanced production of CC-chemokines (RANTES, MCP-1, MIP-la, MIP- 113, and eotaxin) in patients with atopic dermatitis. Arch. Dermatol Res. (2001) 293(7):350–355.
  • TEDLA N, WANG HW, McNEIL HP et al: Regulation of T lymphocyte trafficking into lymph nodes during an immune response by the chemokines macrophage inflammatory protein (MIP)- la and MIP-1 3. j Immunol (1998) 161(10):5663–5672.
  • SABROE I, HARTNELL A, JOPLING LA et al.: Differential regulation of eosinophil chemokine signaling via CCR3 and non-CCR3 pathways. I Immunol (1999) 162(5):2946–2955.
  • PHILLIPS R, STUBBS VE, HENSON MR, WILLIAMS TJ, PEASE JE, SABROE I: Variations in eosinophil chemokine responses: an investigation of CCR1 and CCR3 function, expression in atopy, and identification of a functional CCR1 promoter. I Immunol (2003) 170(12):6190–6201.
  • CAMPBELL EM, KUNKEL SL, STRIETER RM, LUKACS NW: Temporal role of chemokines in a murine model of cockroach allergen-induced airway hyperreactivity and eosinophilia. Immunol (1998) 161(12):7047–7053.
  • GONZALO J-A, LLOYD CM, WEN D et al.: The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airways hyperresponsiveness. Exp. Med. (1998) 188(1):157–167.
  • BLEASE K, MEHRAD B, STANDIFORD TJ et al: Airway remodeling is absent in CCR1 / mice during chronic fungal allergic airway disease. J. Immunol (2000) 165(3):1564–1572.
  • LAFFARGUE M, CALVEZ R, FINAN P et al.: Phosphoinositide 3-kinase-y is an essential amplifier of mast cell function. Immunity (2002) 16(3):441–451.
  • TODA M, DAWSON M, NAKAMURA T et al.: Impact of engagement of Fcc RI and CC chemokine receptor 1 on mast cell activation and motility../. Biol. Chem. (2004) 279(46):48443–48448.
  • MIYAZAKI D, NAKAMURA T, TODA M et al: Macrophage inflammatory protein-la as a costimulatory signal for mast cell-mediated immediate hypersensitivity reactions. J. Clin. Invest. (2005) 115(2):434–442.
  • PROUDFOOT AE, POWER CA, HOOGERWERF AJ et al: Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. Biol. Chem. (1996) 271:2599–2603.
  • PROUDFOOT AE, BUSER R, BORLAT F et al: Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors. J. Biol. Chem. (1999) 274(45):32478–32485.
  • MATSUI M, WEAVER J, PROUDFOOT AE et al: Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES. Neuroimmunol (2002) 128(1-2):16–22.
  • GRONE HJ, WEBER C, WEBER KS et al.: Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J. (1999) 13(11):1371–1383.
  • STOJANOVIC T, BEDKE J, GRONE HJ et al.: Met-RANTES inhibition of mucosal perfusion failure in acute intestinal transplant rejection - role of endothelial cell-leukocyte interaction. I Vasc. Res. (2002) 39(1):51–58.
  • BEDKE J, STOJANOVIC T, GRONE HJ et al.: Met-RANTES improves acute-rejection-induced microvascular injury in rat small bowel transplantation. Transplant. Proc. (2002) 34(3):1049.
  • SONG E, ZOU H, YAO Y et al: Early application of Met-RANTES ameliorates chronic allograft nephropathy. Kidney Int. (2002) 61(2):676–685.
  • YUN JJ, WHITING D, FISCHBEIN MP et al: Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection. Circulation (2004) 109(7):932–937.
  • VEILLARD NR, KWAK B, PELLI G et al: Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ. Re.s (2004) 94(2):253–261.
  • AJUEBOR MN, HOGABOAM CM, KUNKEL SL, PROUDFOOT AE, WALLACE JL: The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat. Immunol (2001) 166(1):552–558.
  • BONVILLE CA, LAU VK, DELEON JM et al.: Functional antagonism of chemokine receptor CCR1 reduces mortality in acute pneumovirus infection in vivo. J. Virol (2004) 78(15):7984–7989.
  • BHATIA M, PROUDFOOT AE, WELLS TN et al.: Treatment with Met-RANTES reduces lung injury in caerulein-induced pancreatitis. Br. J. &mg. (2003) 90(6):698–704.
  • ANDERS HJ, FRINK M, LINDE Y et al: CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration. Immunol (2003) 170(11):5658–5666.
  • PANZER U, SCHNEIDER A, WILKEN J et al.: The chemokine receptor antagonist AOP-RANTES reduces monocyte infiltration in experimental glomerulonephritis. Kidney Int. (1999) 56(6):2107–2115.
  • CHVATCHKO Y, PROUDFOOT AE, BUSER R et al.: Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues is not mediated through CCR3. Immunol (2003) 171(105498–5506.
  • ELSNER J, MACK M, BRUHL H et al: Differential activation of CC chemokine receptors by AOP-RANTES. J. Biol. Chem. (2000) 275(11):7787–7794.
  • MACK M, LUCKOW B, NELSON PJ et al.: Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J. Exp. Med. (1998) 187(8):1215–1224.
  • HESSELGESSER J, NG HP, LIANG M et al.: Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor. J. Biol. Chem. (1998) 273(25):15687–15692.
  • ••The first description of a small-moleculeantagonist of CCR1.
  • RICHELSON E: Preclinical pharmacology of neuroleptics: focus on new generation compounds. J. Clin. Psychiatry (1996) 57(Suppl 11):4–11.
  • CUSACK B, NELSON A, RICHELSON E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl) (1994) 114(4):559–565.
  • LIANG M, MALLARI C, ROSSER M et al.: Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J. Biol. Chem. (2000) 275(25):19000–19008.
  • ••Thorough characterisation of a small-molecule CCR1 antagonist.
  • ANDERS HJ, VIELHAUER V, FRINK M et al: A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J. Clin. Invest. (2002) 109(2):251–259.
  • ••Thorough characterisation of a small-molecule CCR1 antagonist.
  • GLADUE RP, TYLASKA LA, BRISSETTE WH et al.: CP-481715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases. J. Biol. Chem. (2003) 278(42):40473–40480.
  • ••Thorough characterisation of a small-molecule CCR1 antagonist.
  • HORUK R, SHUREY S, NG HP et al: CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model. Immunol Lett (2001) 76(3):193–201.
  • HORUK R, CLAYBERGER C, KRENSKY AM et al.: A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection. J. Biol. Chem. (2001) 276(6):4199–4204.
  • NAYA A, SAGARA Y, OHWAKI K et al: Design, synthesis, and discovery of a novel CCR1 antagonist. J. Med. Chem. (2001) 44(9):1429–1435.
  • NAYA A, ISHIKAWA M, MATSUDA K et al: Structure-activity relationships of xanthene carboxamides, novel CCR1 receptor antagonists. Bioorg. Med. Chem. (2003) 11(6):875–884.
  • SABROE I, PECK MJ, VAN KEULEN B et al: A small molecule antagonist of the chemokine receptors CCR1 and CCR3: potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J. Biol. Chem. (2000) 275(34):25985–25992.
  • DE MENDONCA FL, DA FONSECA PC, PHILLIPS RM et al: Site-directed mutagenesis of CC chemokine receptor 1 reveals the mechanism of action of UCB 35625, a small molecule chemokine receptor antagonist. J. Biol. Chem. (2005) 280(6):4808–4816.
  • ••The first detailed description of how aproteotypic antagonist of CCR1 appears to function at the molecular level.
  • BLANPAIN C, DORANZ BJ, BONDUE A et al.: The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. ./. Biol. Chem. (2003) 278(7):5179–5187.
  • KATH JC, DIRICO AP, GLADUE RP et al: The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template. Bioorg. Med. Chem. Lett. (2004) 14(9):2163–2167.
  • KATH JC, BRISSETTE WH, BROWN MF et al.: Potent small molecule CCR1 antagonists. Bioorg. Med. Chem. Lett. (2004) 14(9):2169–2173.
  • BROWN MF, AVERY M, BRISSETTE WH et al: Novel CCR1 antagonists with improved metabolic stability. Bioorg. Med. Chem. Lett. (2004) 14(9):2175–2179.
  • SALCEDO RHO, OPPENHEIM JJ, WELNIAK LA, BLAZAR BR, MURPHY WJ: Drug Inhibition of graft-versus-host disease by a distamycin analogue that interferes with chemokine receptor function. Blood (1999)94(10 Suppl. 1):(Abstract 1738).
  • ONUFFER J, McCARRICK MA, DUNNING L et al: Structure function differences in nonpeptide CCR1 antagonists for human and mouse CCR1. J. Immunol (2003) 170(4):1910–1916.795 Expert Op/n. lnvestig. Drugs (2005) 14(7)
  • SCHWARZ MK, WELLS TN: New therapeutics that modulate chemokine networks. Nat. Rev Drug Discov. (2002) 1(5):347–358.
  • GARCIA-RAMALL E, MARQUES T, PRATS N et al: Resident cell chemokine expression serves as the major mechanism for leukocyte recruitment during local inflammation. J. Immunol (2002) 169(10:6467–6473.
  • OFFORD R: Peptides - The Wave of the Future (Part II) - Optimization of a superactive anti-HIV compound. Second International and 17th American Peptide Symposium, CA, USA, June 9 — 14 (2001).
  • HORUK R: Society for Medicines Research - Chemokine Receptors and Drug Discovery, Horsham, UK, March 11(2004).
  • LAROSA G: BPS Winter Meeting - Chemokine Antagonists - Future Selective Therapy for Infection, Inflammation, Asthma, Allergy Cancer and Transplantation, London, UK, December 17 (2001).
  • RICE WG TJ, HUANG M, HOWARD OMZ, MICHEJDA CJ, BADER JP: New Types of anti-HIV agents identified by the NCI Drug Discovery Program. 11th International Conference on Antiviral Research, San Diego, CA, USA, April 5— 10 (1999).
  • GLADUE RP: Discovery and characterization of a novel CCR1 antagonist, CP-481715. Inflammation Research Association Conference - Chemokines: Latest Advances and Clinical Outcomes, Boston, MA, USA, February 26 — 27 (2004).
  • GODESSART N: CCR1 blockade in murine models of acute and chronic inflammation. Inflammation Research Association - 11th National Conference (Part VI), Bolton Landing, NY, USA. October 6 — 10 (2002).
  • MADING P: 18F-Labelling of the CCR1 antagonist ZK-811460 for the diagnosis of Alzheimer's disease. Technical Exchange Meeting on Alzheimer Imaging, Berlin, Germany. October 30 (2003).
  • BAUMAN J: CCR1 antagonists. Frontiers in Medicinal Chemistry - Annual Meeting Erlangen, Germany March 15 — 17 (2004).

Websites

  • http://www.chemocentryx.comiproducti forest.html ChemoCentryx Forest Programme pipeline.
  • http://smnorg.uldprevious_meetings/pdf/ march04.pdf Highlights from the Society for Medicines Research meeting March 11(2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.